Avadel Pharmaceuticals (AVDL) Q4 2024 earnings summary

Executive summary

• LUMRYZ, launched in June 2023, achieved nearly $200 million in net sales and 2,500 patients on therapy by year-end 2024, with 74% reimbursed.

• The company is expanding into idiopathic hypersomnia with a Phase 3 trial underway and holds 29–30 Orange Book-listed patents with protection through early 2042.

• FDA approved LUMRYZ for pediatric narcolepsy in Q4 2024, granting Orphan Drug Exclusivity through October 2031.

• Strategic investments include expanding the sales force, doubling nursing and support teams, and enhancing patient and physician interventions.

• The company maintains a strong balance sheet with no debt and positive cash flow achieved in Q4 2024.

Financial highlights

• Q4 2024 net product revenue was $50.4 million, up from $19.5 million in Q4 2023; full-year 2024 revenue reached $169.1 million to nearly $200 million.

• Operating loss narrowed to $42.4 million in 2024 from $137.8 million in 2023; Q4 2024 operating loss was $3.3 million.

• Non-GAAP operating loss for 2024 was $12.3 million, with Q4 2024 showing non-GAAP operating income of $1.8 million.

• Gross profit for Q4 2024 was $45.6 million (90.5% margin); full-year gross profit was $153.8 million (91% margin).

• Cash, cash equivalents, and marketable securities totaled $73.8 million at year-end 2024.

Outlook and guidance

• 2025 revenue guidance is $240–$260 million, with cash operating expenses projected at $180–$200 million and positive cash flow of $20–$40 million.

• Patient count on LUMRYZ expected to rise to 3,300–3,500 by end of 2025.

• Guidance assumes conservative persistency and patient mix, with upside possible from improved demand, mix, and persistency.

• Path to $1 billion in annual revenue requires about 8,000 reimbursed patients; currently at 1,800 reimbursed patients.

• Focus on expanding LUMRYZ adoption beyond early adopters to the broader prescriber base.